Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™ Orphazyme A/SInvestor NewsNo...
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO Orphazyme A/SCompany announcementNo. 03/2022Inside...
Notice to convene Extraordinary General Meeting Orphazyme A/SCompany announcement No. 02/2022www.orphazyme.comCompany Registration No...
Orphazyme updates 2021 financial outlook Orphazyme A/SCompany announcementNo. 01/2022Inside information Company Registration No...
Orphazyme announces changes to the Board of Directors Orphazyme A/SCompany announcementNo. 27/2021Company Registration No. 32266355...
Financial Calendar 2022 Orphazyme A/SCompany announcement No. 26/2021www.orphazyme.comCompany Registration No. 32266355 Copenhagen –...
Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen Orphazyme A/SCompany announcement No. 25/2021Company...
Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C Orphazyme A/SCompany...
Modified long-term share-based incentive program for 2021 Orphazyme A/SCompany announcement No. 23/2021Company Registration No...
Orphazyme provides regulatory and financial updates Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355...
Orphazyme to Present at Cowen & Co. 38th Annual Health Care Conference Orphazyme A/SInvestor news ...
Orphazyme recognizes Rare Disease Day 2018 Orphazyme A/SInvestor news ...
Capital increase of 11,380 shares (equivalent to approximately 0.06% of the existing shares) in Orphazyme A/S as a result of an issue of bonus...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.